Skip to main content
. 2022 Oct 25;90(1):333–348. doi: 10.3233/JAD-220808

Table 2.

Adjusted associations of baseline CSF and SUVR with secondary cognitive outcomes

PiB-PET-positive cohort PiB-PET-positive cohort (SUVR ≥1.49) Overall cohort
RR* 95% CI p RR* 95% CI p RR* 95% CI p
Progression to CDR ≥0.5
  CSF Aβ42 0.55 0.36 0.83 0.004 0.59 0.38 0.91 0.017 0.52 0.35 0.77 0.001
  SUVR (PiB-PET) 0.75 0.63 0.90 0.002 0.78 0.65 0.93 0.006 0.70 0.59 0.84 <0.001
  CSF t-tau 0.97 0.78 1.19 0.764 0.96 0.78 1.19 0.693 0.98 0.78 1.23 0.876
  CSF p-tau 0.67 0.52 0.86 0.002 0.69 0.53 0.89 0.005 0.60 0.46 0.79 <0.001
Progression to CDR ≥1
  CSF Aβ42 0.27 0.13 0.59 0.001 0.29 0.13 0.62 0.002 0.26 0.13 0.51 <0.001
  SUVR (PiB-PET) 0.72 0.55 0.94 0.016 0.74 0.56 0.97 0.028 0.66 0.51 0.87 0.003
  CSF t-tau 0.95 0.74 1.23 0.724 0.94 0.74 1.22 0.681 0.96 0.74 1.25 0.751
  CSF p-tau 0.57 0.36 0.89 0.015 0.59 0.37 0.92 0.020 0.50 0.32 0.78 0.002
CDR-SB ≥4.5 at last visit#
  CSF Aβ42 0.36 0.18 0.70 0.003 0.38 0.19 0.74 0.005 0.32 0.18 0.58 <0.001
  SUVR (PiB-PET) 0.78 0.63 0.96 0.018 0.79 0.64 0.98 0.030 0.73 0.59 0.90 0.004
  CSF t-tau 1.09 0.85 1.39 0.492 1.09 0.85 1.37 0.520 1.12 0.88 1.43 0.366
  CSF p-tau 0.47 0.29 0.75 0.002 0.48 0.30 0.76 0.002 0.40 0.25 0.64 <0.001
MMSE ≤24 at last visit#
  CSF Aβ42 0.30 0.17 0.54 <0.001 0.32 0.18 0.59 <0.001 0.26 0.15 0.45 <0.001
  SUVR (PiB-PET) 0.81 0.64 1.03 0.094 0.83 0.66 1.06 0.135 0.75 0.59 0.96 0.022
  CSF t-tau 0.98 0.69 1.39 0.931 0.97 0.70 1.35 0.872 1.02 0.72 1.45 0.921
  CSF p-tau 0.61 0.40 0.94 0.026 0.64 0.42 0.97 0.036 0.52 0.34 0.81 0.003

*Relative risk (RR) is with a one standard deviation higher in CSF Aβ42 levels and lower in CSF t-tau, CSF p-tau, and SUVR levels. CI, confidence interval; CDR, clinical dementia rating; CSF, cerebrospinal fluid; Aβ42, 42-amino acid amyloid-beta peptide; t-tau, total tau; p-tau, phospho-Tau; CDR-SB, CDR sum of boxes; PiB-PET, Pittsburgh compound B positron emission tomography; SUVR, standardized uptake value ratio; MMSE, Mini-Mental State Examination; FDG, fluorodeoxyglucose. All CSF and SUVR values are standardized. Analysis adjusted for mean mutation age of symptom onset, sex, education, APOE4 status, and duration of follow up. #Analyses were also adjusted for baseline CDR-SB or MMSE; Overall cohort includes PiB-PET-positive and negative samples.